A New Face of Aldosterone;Aldosteron - Hormon o nowym obliczu

Nadcisnienie Tetnicze

Volumn 7, Issue 4, 2003, Pages 271-279

  Dobrucki, Tomasz ^a   Januszewicz, Andrzej ^a   Sitkiewicz, Dariusz ^a   Januszewicz, Włodzimierz ^b  

^a INSTITUTE OF CARDIOLOGY   (Poland)

^b Klinika Nadcisnienia Tetniczego ^*

Author keywords

Aldosterone; Aldosterone antagonists; Biological activity; Cardiovascular risk; Congestive heart failure; Hypertension

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; COLLAGEN; EPLERENONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SPIRONOLACTONE;

ANIMAL MODEL; ARTERY COMPLIANCE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLLAGEN METABOLISM; CONGESTIVE HEART FAILURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; END ORGAN DAMAGE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM INJURY; EXTRACELLULAR FLUID; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE ARRHYTHMIA; HEMODYNAMICS; HORMONE ACTION; HORMONE INHIBITION; HOSPITALIZATION; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; KIDNEY DISEASE; KIDNEY FIBROSIS; LUNG ARTERY; MORTALITY; NONHUMAN; ORGAN INJURY; REVIEW; VASCULAR ENDOTHELIUM; VASCULAR FIBROSIS; VASOCONSTRICTION; VASODILATATION;

EID: 0842328331     PISSN: 14285851     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Kaplan N. Kaplan's Clinical Hypertension. Lippincott Williams & Wilkins. Philadelphia 2002.
2. Czekalski S. Rola układu dokrewnego w regulacji ciśnienia tȩtniczego. W: Krupa-Wojciechowska B., Rutkowski B. (red.). Nadciśnienie tȩtnicze w codziennej praktyce. MAKmed, Gdańsk 1997.
3. Januszewicz A., Ignatowska-Świtalska H. Pierwotny hiperaldosteronizm. W: Januszewicz A., Januszewicz W., Szczepań ska-Sadowska E., Sznajderman M. (red.). Nadciśnienie tȩtnicze. Medycyna Praktyczna, Kraków 2000.
4. Foster R.H., MacFarlane C.H., Bustamante M.O. Recent progress in understanding aldosterone secretion. Gen. Pharmac. 1997; 28: 647-651.
5. Epstein M. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction; a paradigm shift. J. Hypertens. 2001; 19: 829-842.
6. Young M.J., Funder J.W. Mineralocorticoid receptors and pathophysiological roles of aldosterone in the cardiovascular system. J. Hypertens. 2002; 20: 1465-1468.
7. Park J., Schiffrin E.L. Hypertrophy in aldosterone-infused rats: role of endothelin-1. Am. J. Hypertens. 2002; 15: 164-169.
8. Auchus R.J. Aldo is back: recent advances and unresolved controversies in hyperaldosteronism. Curr. Opin. Nephrol. Hypertens. 2003; 12: 153-159.
9. Ibrahim H.N., Hostetter T.H. Aldosterone in renal disease. Curr. Opin. Nephrol. Hypertens. 2003; 12: 159-165.
10. Tuck M. Does aldosterone modulate central control of blood pressure? J. Hypertens. 2002; 20: 1079-1080.
11. Zdrojewicz Z., Sztuka-Pietkiewicz A., Pietkiewicz W. Rola receptorów mineralokortykoidowych w patogenezie nadciśnienia tȩtniczego. Nadciśnienie Tȩtnicze 2000; 3: 209-215.
12. Fuller P.J. Aldosterone's effects and mechanism of action. Curr. Opin. Endocrol. Diabet. 1997; 4: 218-224.
13. Alzamora R., Michea L., Marusic E.T. Role of 11β-hydroxysteroid dehydrogenase on nongenomic aldosterone effetcs in human arteries. Hypertension 2000; 35: 1099-1104.
14. Bonvalet J.P., Alfaidy N., Farman N. i wsp. Aldosterone: intracellular receptors in human heart. Eur. Heart J. 1995; 16 (supl. N): 92-97.
15. Christ M., Douwes K., Eisen C. i wsp. Rapid effects of aldosterone on sodium transport in vascular smooth muscle cells. Hypertension 1995; 25: 117-123.
16. 2+ in vascular smooth muscle cells. Circ. Res. 1995; 76: 973-979.
17. 1 receptor subtype as a cardiac target of aldosterone. Role in aldosterone-salt-induced fibrosis. Hypertension 1999; 33: 981-986.
18. Funder J.W. Central effects of mineralocorticoids on blood pressure: new answers, new questions. J. Hypertens. 2002; 20: 1715-1716.
19. Kornel L. Colocalisation of 11β-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells. Am. J. Hypertens. 1994; 7 (1): 100-103.
20. Takeda Y., Miyamori I., Yoneda T. i wsp. Production of aldosterone in isolated rat blood vessels. Hypertension 1995; 25: 170-173.
21. Takeda Y., Miyamori I., Inaba S. i wsp. Vascular aldosterone in geneticaly hypertensive rats. Hypertension 1997; 29: 45-48.
22. Silvestre J.S., Robert V., Heymes C. i wsp. Myocardial production of aldosterone and corticosterone in the rat. J. Biol. Chem. 1998; 273 (9): 4883-4891.
23. Gomez-Sanchez C.E., Foecking M.F., Gomez-Sanchez E.P. Aldosterone esters and the heart. Am. J. Hypertens. 2001; 14: 200S-205S.
24. Young M., Fullerton M., Dilley R., Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J. Clin. Invest. 1994; 93: 2578-2583.
25. Nicoletti A., Heudes D., Hinglais N. i wsp. Left ventricular fibrosis in renovascular hypertensive rats. Hypertension 1995; 26: 101-111.
26. Schunkert H., Hense H.W., Muscholl M. i wsp. Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart 1997; 77: 24-31.
27. Brilla C.G., Weber K.T. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J. Lab. Clin. Med. 1992; 120: 893-901.
28. Brilla C.G., Matsubara L.S., Weber K.T. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am. J. Cardiol. 1993; 71: 12A-16A.
29. Benetos A., Lacolley P., Safar M.E. Prevention of aortic fibrosis by spironolactone in spontaneusly hypertensive rats (SHR). Arteriosclerosis Thromb. Vasc. 1997; 17: 1152-1156.
30. Ulian M.E., Schelling J.R., Linas S.L. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension 1992; 20: 67-73.
31. Brown N.J., Kim K., Chen Y. i wsp. Synergistic effect of adrenal steroid and angiotensin II on plasminogen activator inhibitor-1 production. J. Clin. Endocrinol. Metab. 2000; 85: 336-344.
32. Rocha R., Chander P.N., Khanna K. i wsp. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31: 457-458.
33. Rocha R., Chander P.N., Zuckerman A., Stier C.T. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33 (2): 232-237.
34. Gomez-Sanchez E.P. Mineralocorticoid modulation of central control of blood pressure. Steroids 1995; 60: 69-72.
35. Rahmouni K., Barthelmebs M., Grima M. i wsp. Influence of sodium intake on the cardiovascular and renal effects of brain mineralocorticoid receptor blockade in normotensive rats. J. Hypertens. 2002; 20: 1829-1834.
36. Tanaka J., Fujita H., Matsuda S. i wsp. Glucocorticoid and mineralocorticoid receptors in microglial cells: the two receptors mediate differential effects of corticosteroids. Glia 1997; 20: 23-37.
37. Sosa-Leon L.A., McKinley M.J., McAllen R.M., May C.N. Aldosterone acts on the kidney, not the brain, to cause mineralocorticoid hypertension in sheep. J. Hypertens. 2002; 20: 1203-1208.
38. Wang W. Chronic administration of aldosterone depressed baroreceptor reflex function in the dog. Hypertension 1994; 24: 571-575.
39. Yee K.M., Struthers A.D. Aldosterone blunts baroreflex response in man. Clin. Sci. 1998; 95: 687-692.
40. Weber M.A., Purdy R.E. Catecholamine-mediated effects of aldosterone on vascular smooth muscle. Life Sci. 1982; 30: 2009-2017.
41. Yee K.M., Pringle S.D., Struthers A.D. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J. Am. Coll. Cardiol. 2001; 37: 1800-1807.
42. Genest J., Koiw E., Nowaczyński W. i wsp. Study of a large steroid spectrum in normal subjects and hypertensive patients. Acta Endocr. 1960; 35: 413.
43. Laragh J.H., Ulick S., Januszewicz W. i wsp. Aldosterone secretion in primary and malignant hypertension. J. Clin. Invest. 1960; 39: 1091-1106.
44. Laragh J.H., Ulick S., Januszewicz W. i wsp. Electrolite metabolism and aldosterone secretion in benign and malignant hypertension. Ann. Int. Med. 1960; 53: 259-272.
45. Schlaich M.P., Klingbeil A., M. Jacobi J. i wsp. Altered aldosterone response to salt intake and angiotensin II infusion in young normotensive men with parental history of arterial hypertension. J. Hypertens. 2002; 20: 117-124.
46. Yamamoto N., Yasue H., Mizuno Y. i wsp. Aldosterone is produced from ventricles in patients with essential hypertension. Hypertension 2002; 39: 958-962.
47. Grandi A.M., Imperiale D., Santillo R. i wsp. Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension 2002; 40: 647-652.
48. Januszewicz W., Sznajderman M. Patogeneza nadciśnienia tȩ;tniczego - nowe spojrzenie. W: Naruszewicz M. (red.). Kardiologia zapobiegawcza. Szczecin 2003.
49. Hayoz D. Left ventricular hypertrophy and remodeling of resistance arteries: the role of activation of the renin-angiotensin-aldosterone system in hypertension. J. Hypertens. 2002; 20: 1295-1296.
50. Kokot F., Ficek R. Patogenetyczne i lecznicze aspekty układu reninowo-angiotensynowo-aldosteronowego (RAA) wczoraj i dziś. Kardiol. Pol. 2001; 54: 295-301.
51. Januszewicz W., Sznajderman M., Szczepańska-Sadowska E. Nadciśnienie tȩtnicze. PZWL, Warszawa 1993.
52. Stowasser M. Primary aldosteronism: revival of a syndrome. J. Hypertens. 2000; 18: 363-366.
53. Rossi G.P., Sacchetto A., Vissentin P. i wsp. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996; 27: 1039-1045.
54. Rossi G.P., Di Bello V., Ganzaroli C. i wsp. Excess aldosterone is associated with alterations in myocardial texture in primary aldosteronism. Hypertension 2002; 40: 23-27.
55. Prejbisz A., Postula M., Cybulska I. i wsp. Badania biochemiczne i symptomatologia kliniczna w diagnostyce i różnicowaniu postaci pierwotnego hiperaldosteronizmu. Kardiol. Pol. 2003; 58: 22-26.
56. Brown N.J., Nakamura S., Ma L. i wsp. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int. 2000; 58: 1219-1227.
57. Ciechanowicz A., Januszewicz A., Januszewicz W., Ruzyłło W. (red.). Genetyka chorób ukladu kra̧żenia. Medycyna Praktyczna, Kraków 2002.
58. Warnock D.G. Genetic forms of human hypertension. Curr. Opin. Nephrol. Hypertens. 2001; 10: 493-499.
59. Dluhy R.G., Lifton R. Glucocorticoid-remediable aldosteronism. J. Clin. Endocrinol. Metab. 1999; 84: 4341-4344.
60. Mizuno Y., Yoshimura M., Yasue H. i wsp. Aldosterone production is activated in failing ventricle in humans. Circulation 2001; 103: 72-77.
61. Cicoira M., Zanolla L., Rossi A. i wsp. Long term, dose-dependend effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J. Am. Coll. Cardiol. 2002; 40: 304-310.
62. Schmidt B.M.W., Schmieder R.E. Aldosterone-induced cardiac damage: focus on blood pressure independent effects. Am. J. Hypertens. 2003; 16: 80-86.
63. Pitt B., Zannad F., Remme W. i wsp. for the Randomised Aldactone Evaluation Study Investigators: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 1999; 341: 709-717.
64. Jessup M. Aldosterone blockade and heart failure. N. Engl. J. Med. 2003; 248: 1380-1382.
65. Zannad F., Alla F., Donsset B. i wsp. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation 2000; 102: 2700-2706.
66. Modena M.G., Aveta P., Menozzi A. i wsp. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am. Heart J. 2001; 141: 41-46.
67. Farquharson C.A.J., Struthers A.D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101: 594-597.
68. Hayashi M., Tsutamoto T., Wada A. i wsp. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003; 107: 2559-2565.
69. Brown N.J. Eplerenone. Cardiovascular protection. Circulation 2003; 107: 2512-2518.
70. Pitt B., Remme W., Zannad F. i wsp. for Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003; 348: 1309-1321.
71. Pitt B. Aldosterone blockade in patients with acute myocardial infarction. Circulation 2003; 107: 2525-2527.
72. Chobanian A. Report of the JNC 7 report on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003; 289: 2560-2572.
73. Weinberger M.H., Roniker B., Krause S.L., Weiss R.J. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. 2002; 15: 709-716.
74. Krum H., Nolly H., Workman D. i wsp. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002; 40: 117-123.
75. White W.B., Duprez D., St-Hillaire R. i wsp. Effects of the selective aldosterone blocker eplerenonc versus the calcium antagonist amlodypine in systolic hypertension. Hypertension 2003; 41: 1021-1026.
76. Rajagopalan S., Duqaine D., Pitt B. i wsp. Aldosterone receptor antagonism improves endothelial function in diet induced atherosclerosis. Twenty-sewenth International Aldosterone Conference. Denver 2001.